Andreas Machens, Henning Dralle. Show Affiliations »
Abstract
Entities: Disease
Mesh： See more » Administration, OralBenzenesulfonates/administration & dosageBenzenesulfonates/therapeutic useBiomarkers, Tumor/metabolismCalcitonin/metabolismCarcinoembryonic Antigen/metabolismCarcinoma, Medullary/drug therapyCarcinoma, Medullary/enzymologyCarcinoma, Medullary/geneticsCarcinoma, Medullary/mortalityCarcinoma, Medullary/secondaryClinical Trials, Phase II as TopicDisease-Free SurvivalHumansLymph Node ExcisionLymphatic MetastasisNiacinamide/analogs & derivativesPhenylurea CompoundsProtein Kinase Inhibitors/administration & dosageProtein Kinase Inhibitors/therapeutic usePyridines/administration & dosagePyridines/therapeutic useSorafenibThyroid Neoplasms/drug therapyThyroid Neoplasms/enzymologyThyroid Neoplasms/geneticsThyroid Neoplasms/mortalityThyroid Neoplasms/pathologyTreatment Outcome
Substances： See more » BenzenesulfonatesBiomarkers, TumorCarcinoembryonic AntigenPhenylurea CompoundsProtein Kinase InhibitorsPyridinesNiacinamideCalcitoninSorafenib
Year: 2010 PMID： 20713862 DOI： 10.1200/JCO.2010.29.9909
Source DB: PubMed Journal: J Clin Oncol ISSN： 0732-183X Impact factor: 44.544